Sten Stovall
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
Sensyne Health CEO Drayson Says IPO Will See AI Group To Profitability
Flush with IPO funding, AI-focused healthcare technology group Sensyne Health will now ready additional products and find three more NHS trust partnerships. CEO Lord Drayson spoke to Scrip.
Stand-Off: Vertex Refuses NICE Data on CF Drug Symkevi, HTA Body Awaits Next Move
Vertex says it will not file data on its cystic fibrosis drug Symkevi (tezacaftor/ivacaftor) until the UK's NICE changes the way it assesses drugs.
With Novo Nordisk Dependent On GLP-1s, Even Perceived Price Pressures Can Hurt
Long-term top-line market forecasts for Novo Nordisk are heavily reliant on its GLP-1 portfolio's potential - so pricing uncertainties, especially in the US, can unnerve sentiment, as seen when it reported Q2 results.
Seeking Efficiencies, Novo Nordisk To Squeeze Costs, Boost Growth Drivers
Novo Nordisk aims to offset US pricing pressures with increased cost management, freeing investment for key growth drivers like Ozempic and oral Semaglutide.
Allergan And Editas Sharpen Their CRISPR Focus On Ocular Drugs
Allergan and CRISPR specialist Editas have reinforced their gene editing R&D pact launched in March 2017.
Arix Taps Australia's 'Undervalued' Pharmaxis As First VIPE, More Planned
UK-listed Arix completed its first Venture Investment in Public Equity (VIPE), leading a A$24m (£13.4m) investment in Australian biotech Pharmaxis.